|MDACC Study No:||2011-0987 (clinicaltrials.gov NCT No: NCT01515527)|
|Title:||PHASE II STUDY OF CLADRIBINE PLUS LOW DOSE CYTARABINE (LDAC) INDUCTION FOLLOWED BY CONSOLIDATION WITH CLADRIBINE PLUS LDAC ALTERNATING WITH DECITABINE IN PATIENTS WITH UNTREATED AML OR HIGH-RISK MDS|
|Principal Investigator:||Tapan Kadia|
|Treatment Agent:||Cladribine; Cytarabine; Decitabine|
|Study Description:||The goal of this clinical research study is to learn if cladribine given in |
combination with low-dose cytarabine (LDAC) and decitabine can help control the
disease in patients with AML or MDS. The safety of this drug combination will
also be studied.
Cladribine is designed to interfere with the cell's ability to process DNA (the
genetic material of cells). It can also insert itself into the DNA of cancer
cells to stop them from growing and repairing themselves.
Cytarabine is designed to insert itself into DNA of cancer cells to stop them
from growing and repairing themselves.
Decitabine is designed to damage the DNA of cells, which may cause cancer cells